Mail

UK markets closed

FTSE 100
8,139.83
+60.97(+0.75%)
FTSE 250
19,824.16
+222.18(+1.13%)
AIM
755.28
+2.16(+0.29%)
GBP/EUR
1.1679
+0.0022(+0.19%)
GBP/USD
1.2494
-0.0017(-0.13%)
Bitcoin GBP
50,201.18
-1,372.21(-2.66%)

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Vor Biopharma Inc. (VOR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

1.6900

-0.0100

(-0.59%)

At close: 04:00PM EDT

1.6900

0.00

(0.00%)

After hours:

04:20PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	115.97M
Enterprise value	14.45M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	0.77
Enterprise value/revenue	N/A
Enterprise value/EBITDA	-0.12

Trading information

Stock price history

Beta (5Y monthly)	-0.37
52-week change ³	-61.80%
S&P500 52-week change ³	22.36%
52-week high ³	5.7000
52-week low ³	1.6200
50-day moving average ³	2.0162
200-day moving average ³	2.2701

Share statistics

Avg vol (3-month) ³	327.72k
Avg vol (10-day) ³	231.06k
Shares outstanding ⁵	68.22M
Implied shares outstanding ⁶	68.22M
Float ⁸	31.89M
% held by insiders ¹	1.16%
% held by institutions ¹	88.56%
Shares short (15 Apr 2024) ⁴	3.39M
Short ratio (15 Apr 2024) ⁴	9.04
Short % of float (15 Apr 2024) ⁴	9.14%
Short % of shares outstanding (15 Apr 2024) ⁴	4.97%
Shares short (prior month 15 Mar 2024) ⁴	3.07M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	0.00%

Management effectiveness

Return on assets (ttm)	-31.67%
Return on equity (ttm)	-58.74%

Income statement

Revenue (ttm)	N/A
Revenue per share (ttm)	N/A
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-122.54M
Net income avi to common (ttm)	-117.86M
Diluted EPS (ttm)	-1.7500
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	137.18M
Total cash per share (mrq)	2.01
Total debt (mrq)	35.66M
Total debt/equity (mrq)	23.66%
Current ratio (mrq)	9.04
Book value per share (mrq)	2.22

Cash flow statement

Operating cash flow (ttm)	-100.29M
Levered free cash flow (ttm)	-58.02M